News
Dr. Alessandro Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer
Alessandro Santin, MD, professor, Obstetrics, Gynecology, and Reproductive Sciences, Disease Aligned Research Team Leader, Gynecologic Oncology Program, co-chief, Section of Gynecologic Oncology, Yale Cancer Center, discusses the investigation of sacituzumab govitecan-hziy (Trodelvy) in patients with recurrent endometrial carcinoma overexpressing TROP2.
Investigators launched a 2-stage phase 2 clinical trial (NCT04251416) to evaluate the use of sacituzumab govitecan in this patient population. The preliminary responses from this study were presented at the 2023 ASCO Annual Meeting.
Source: OncLive